Technical Analysis for ALPMY - Astellas Pharma Inc

Grade Last Price % Change Price Change
grade D 16.04 -0.16% -0.0250
ALPMY closed down 0.16 percent on Wednesday, July 8, 2020, on 73 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ALPMY trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -0.16%
Stochastic Reached Oversold Weakness -0.16%
Gapped Down Weakness -0.16%
Oversold Stochastic Weakness -0.16%
Narrow Range Bar Range Contraction -2.73%
Outside Day Range Expansion -2.73%
MACD Bearish Centerline Cross Bearish -2.85%
Older signals for ALPMY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Chemistry Medicine Diabetes Hypertension Prostate Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Organic Chemistry Benign Prostatic Hyperplasia Non Small Cell Lung Cancer Mitsubishi Ufj Financial Group Hyperplasia Lactams Overactive Bladder Adult Bronchial Asthma Astellas Pharma Enzalutamide Exports Pharmaceutical Products Hypercholesterolemia Tamsulosin Treatment For Hypertension Treatment For Non Small Cell Lung Cancer Treatment For Osteoporosis Treatment Of Prostate Cancer

Is ALPMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.43
52 Week Low 12.48
Average Volume 70,882
200-Day Moving Average 16.3157
50-Day Moving Average 16.6875
20-Day Moving Average 16.5998
10-Day Moving Average 16.5975
Average True Range 0.4483
ADX 11.04
+DI 22.2808
-DI 34.7045
Chandelier Exit (Long, 3 ATRs ) 16.1151
Chandelier Exit (Short, 3 ATRs ) 17.3449
Upper Bollinger Band 17.3096
Lower Bollinger Band 15.8900
Percent B (%b) 0.11
BandWidth 8.5519
MACD Line -0.1088
MACD Signal Line -0.0146
MACD Histogram -0.0943
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.5650
Resistance 3 (R3) 16.6100 16.4800 16.4775
Resistance 2 (R2) 16.4800 16.3463 16.4575 16.4483
Resistance 1 (R1) 16.2600 16.2637 16.1950 16.2150 16.4192
Pivot Point 16.1300 16.1300 16.0975 16.1075 16.1300
Support 1 (S1) 15.9100 15.9963 15.8450 15.8650 15.6608
Support 2 (S2) 15.7800 15.9137 15.7575 15.6317
Support 3 (S3) 15.5600 15.7800 15.6025
Support 4 (S4) 15.5150